𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the role of rituximab

✍ Scribed by Domenica Caramazza; Gerlando Quintini; Ignazio Abbene; Alessandra Malato; Giorgia Saccullo; Lucio Lo Coco; Rosa Di Trapani; Roberto Palazzolo; Rita Barone; Giuseppina Mazzola; Sergio Rizzo; Paolo Ragonese; Paolo Aridon; Vincenzo Abbadessa; Sergio Siragusa

Book ID
109146073
Publisher
Elsevier Science
Year
2010
Tongue
English
Weight
189 KB
Volume
50
Category
Article
ISSN
0372-1248

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Role of splenectomy in patients with ref
Role of splenectomy in patients with refractory or relapsed thrombotic thrombocytopenic purpura
✍ Nicole A. Aqui; Steven H. Stein; Barbara A. Konkle; Charles S. Abrams; Frank J. πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 67 KB

## Abstract Thrombotic thrombocytopenic purpura (TTP) was once uniformly fatal. Therapeutic plasma exchange in combination with immunosuppressive and anti‐platelet agents, however, have resulted in improved survival rates of greater than 80% for patients with TTP. In spite of aggressive plasma exch

Rituximab for the treatment of refractor
Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): Report of three cases
✍ Lydia Koulova; Doru Alexandrescu; Janice P. Dutcher; Kevin P. O'Boyle; Saji Eape πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 162 KB πŸ‘ 2 views

Three patients (one with idiopathic thrombocytopenic purpura [ITP] and two with thrombotic thrombocytopenic purpura [TTP]) were treated with rituximab (anti-CD20 chimeric antibody) at a dose of 325 mg/m 2 administered weekly after they failed standard therapies. The patient with ITP who did not resp